NewEdge Wealth LLC Purchases 40,382 Shares of Genmab A/S (NASDAQ:GMAB)

NewEdge Wealth LLC lifted its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 50.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 119,989 shares of the company's stock after purchasing an additional 40,382 shares during the quarter. NewEdge Wealth LLC's holdings in Genmab A/S were worth $3,820,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. First Manhattan Co. acquired a new position in shares of Genmab A/S in the 4th quarter valued at approximately $26,000. Headlands Technologies LLC acquired a new position in shares of Genmab A/S in the 3rd quarter valued at approximately $27,000. Pinnacle Bancorp Inc. raised its position in shares of Genmab A/S by 315.8% in the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company's stock valued at $27,000 after purchasing an additional 638 shares in the last quarter. NBC Securities Inc. acquired a new stake in shares of Genmab A/S during the 3rd quarter valued at approximately $37,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Genmab A/S by 86.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company's stock valued at $38,000 after acquiring an additional 498 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on GMAB. Truist Financial reissued a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research report on Tuesday, March 26th. Morgan Stanley restated an "underweight" rating on shares of Genmab A/S in a research note on Tuesday, March 26th. BMO Capital Markets upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $46.00 to $48.00 in a research note on Friday, February 23rd. Citigroup downgraded Genmab A/S from a "neutral" rating to a "sell" rating in a research note on Monday, January 22nd. Finally, HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, April 4th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $48.50.

Genmab A/S Trading Down 1.6 %

GMAB stock traded down $0.48 during trading hours on Friday, hitting $29.26. 413,219 shares of the stock traded hands, compared to its average volume of 390,206. Genmab A/S has a one year low of $26.32 and a one year high of $42.99. The company has a market cap of $19.33 billion, a P/E ratio of 30.48, a P/E/G ratio of 2.10 and a beta of 0.99. The stock has a 50-day simple moving average of $29.27 and a 200 day simple moving average of $30.45.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.34 by $0.02. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The business had revenue of $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. Analysts forecast that Genmab A/S will post 1.06 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.